What is HC Wainwright’s Forecast for NTLA Q3 Earnings?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities research analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Intellia Therapeutics in a note issued to investors on Wednesday, March 5th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings per share of ($1.48) for the quarter. HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. HC Wainwright also issued estimates for Intellia Therapeutics’ FY2025 earnings at ($5.71) EPS, Q1 2026 earnings at ($1.48) EPS, Q2 2026 earnings at ($1.48) EPS, Q3 2026 earnings at ($1.54) EPS and FY2026 earnings at ($5.67) EPS.

NTLA has been the subject of several other reports. William Blair reissued a “neutral” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a research report on Monday, November 18th. Wells Fargo & Company lowered their price objective on Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Canaccord Genuity Group reissued a “buy” rating and issued a $90.00 price objective on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Oppenheimer lowered their price objective on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a research report on Monday, January 13th. Finally, Truist Financial lowered their price objective on Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday. Two analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Intellia Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $37.56.

Intellia Therapeutics Trading Up 5.8 %

NTLA stock opened at $9.90 on Friday. The stock has a 50-day moving average price of $10.64 and a 200-day moving average price of $15.28. Intellia Therapeutics has a 1-year low of $8.30 and a 1-year high of $32.00. The firm has a market cap of $1.02 billion, a PE ratio of -1.82 and a beta of 1.97.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the transaction, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders sold 29,000 shares of company stock worth $352,551. Insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Capstone Investment Advisors LLC boosted its stake in shares of Intellia Therapeutics by 1.4% in the 3rd quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company’s stock worth $1,256,000 after buying an additional 831 shares during the last quarter. KBC Group NV boosted its stake in shares of Intellia Therapeutics by 37.3% in the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock worth $77,000 after buying an additional 1,020 shares during the last quarter. Axxcess Wealth Management LLC boosted its stake in shares of Intellia Therapeutics by 5.4% in the 3rd quarter. Axxcess Wealth Management LLC now owns 20,215 shares of the company’s stock worth $415,000 after buying an additional 1,044 shares during the last quarter. Ensign Peak Advisors Inc boosted its stake in shares of Intellia Therapeutics by 2.9% in the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company’s stock worth $457,000 after buying an additional 1,100 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Intellia Therapeutics by 10.3% in the 3rd quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock worth $320,000 after buying an additional 1,538 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.